Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00024427 · ClinicalTrials.gov registry record · Phase 3
Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Wellstat Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 250
- Enrollment target
NCT00024427 is a Phase 3 study that has completed, run by Wellstat Therapeutics. The registered enrollment target is 250 participants.
The verdict
NCT00024427, a Phase 3 study, has completed, sponsored by Wellstat Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 250 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells. Chemoprotective drugs such as triacetyluridine may protect normal cells from the side effects of chemotherapy. It is not yet known which chemotherapy regimen is more effective in treating pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of fluorouracil plus triacetyluridine with that of gemcitabine in treating patients who have locally advanced or metastatic pancreatic cancer that cannot be treated with surgery.
Interventions
- DRUG fluorouracil
- DRUG gemcitabine hydrochloride
- DRUG triacetyluridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2001-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00024427
The ClinicalTrials.gov registry entry for NCT00024427 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wellstat Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fluorouracil is the first listed.
NCT00024427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00024427 about?
NCT00024427 is a clinical study titled "Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells. Chemoprotective drugs such as triacetyluridine may protect normal cells from the side effects of chemotherapy....
What is the current status of trial NCT00024427?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2001-02.
What interventions are being tested in trial NCT00024427?
The interventions under investigation include: fluorouracil (DRUG), gemcitabine hydrochloride (DRUG), triacetyluridine (DRUG).
Who is sponsoring clinical trial NCT00024427?
This trial is sponsored by Wellstat Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.